2seventy bio (NASDAQ:TSVT) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 2seventy bio (NASDAQ:TSVT) in a report published on Saturday morning,Weiss Ratings reports.

2seventy bio Trading Up 7.0 %

NASDAQ TSVT traded up $0.17 during mid-day trading on Friday, reaching $2.61. 380,020 shares of the company’s stock traded hands, compared to its average volume of 398,038. 2seventy bio has a 1-year low of $2.35 and a 1-year high of $6.40. The company has a fifty day simple moving average of $3.28 and a 200-day simple moving average of $4.15. The company has a market cap of $134.65 million, a price-to-earnings ratio of -1.40 and a beta of 1.76.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in 2seventy bio by 1.1% during the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after buying an additional 13,144 shares in the last quarter. XTX Topco Ltd increased its stake in 2seventy bio by 61.1% during the third quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock valued at $115,000 after purchasing an additional 9,257 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of 2seventy bio by 9.0% during the third quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock worth $1,237,000 after purchasing an additional 21,673 shares during the period. Western Standard LLC bought a new position in shares of 2seventy bio in the 3rd quarter worth about $1,350,000. Finally, State Street Corp boosted its holdings in shares of 2seventy bio by 1.5% in the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after buying an additional 15,638 shares during the period. 93.90% of the stock is currently owned by institutional investors.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.